Brazil institute says CoronaVac efficacy above 50%, but delays full results

FILE PHOTO: A display shows packages of vaccine candidate for SARS-CoV-2 by Sinovac Biotech during a government-organized media tour showcasing the company's development of a coronavirus disease (COVID-19) vaccine candidate in Beijing, China, September 24, 2020. REUTERS/Thomas Peter

RIO DE JANEIRO (Reuters) - Brazilian researchers said on Wednesday the COVID-19 vaccine developed by China's Sinovac Biotech is more than 50% effective based on trial data, but again withheld full results at the company's request, raising questions about transparency.

Brazil is the first country to complete a late-stage trial of the vaccine, called CoronaVac, but a release of the results, first set for early December, has now been delayed three times.